adplus-dvertising
Connect with us

Business

Brazil researchers now say China's Sinovac vaccine is 50% effective — lower than announced earlier – CNBC

Published

 on


Covid-19 vaccines developed by China’s Sinovac Biotech are displayed during a press conference in Beijing on Sept. 24, 2020.
Wang Zhao | AFP | Getty Images

The Covid-19 vaccine developed by China’s Sinovac Biotech is just 50.4% effective in a Brazilian trial — barely meeting the threshold for regulatory approval and well below the initially reported efficacy rate, according to several media reports.  

Brazil is the first to complete late-stage trial of the vaccine CoronaVac. The state-run Butantan Institute has been criticized by scientists and health experts for a lack of transparency in making public its trial data.

The institute reportedly delayed releasing trial results three times — which it blamed on a confidentially clause in its contract with Sinovac — and last week announced partial data that showed an efficacy rate that was later revised much lower.

Butantan said last week that CoronaVac was 78% effective among volunteers with mild to severe infections, reported the Wall Street Journal. But the institute said Tuesday that the overall efficacy rate fell to 50.4% when including “very mild” cases that did not require medical assistance, the Journal reported.   

In comparison, Covid vaccines from PfizerBioNTech and Moderna were found to be about 95% effective in their late-stage trials.

Sinovac did not immediately respond to CNBC’s emailed request for comment.

Hope for China’s vaccines

Brazil and other developing nations have pinned their hopes on Chinese vaccines as wealthier countries snap up vaccines developed in the West.

Sinovac’s CoronaVac vaccine is also cheaper and easier to transport because it can be stored in ordinary refrigerators — unlike the vaccines from Pfizer-BioNTech and Moderna that must be kept at subfreezing temperatures.

The South American country has reported more than 8.1 million Covid infections in total, the third highest number globally, according to data compiled by Johns Hopkins University. The country’s death toll of over 204,000 is the second highest in the world, Hopkins data showed.

Butantan has requested for CoronaVac to be authorized for emergency use, reported Reuters. Brazil’s health regulator Anvisa, which has stipulated a minimum 50% efficacy rate for vaccines in the pandemic, said it will meet on Sunday to decide, the news agency said.

Trials in other countries

In addition to Brazil, other developing countries including Turkey and Indonesia are also conducting trials on CoronaVac.

Indonesia on Monday approved the vaccine for emergency use — the first country outside China to do so after interim data from a late-stage trial showed that CoronaVac was 65.3% effective, reported Reuters.

Meanwhile, Turkish researchers said their interim analysis showed the vaccine to be 91.25% effective, Reuters reported last month.

Experts quoted by the news agency said it’s not unusual for differential trials of a vaccine to show differing efficacy rates. But fragmental releases of CoronaVac trial data could add to skepticism and undermine confidence in the vaccine, Reuters said.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending